Youtube
DIVISLAB

Divi's Laboratories Ltd.

₹4269.5

Score

32

Technically Bearish

Advice

Divi's Laboratories Price Change Analysis

Divi's Laboratories Key Statistics
  • P/E Ratio

    59.2

  • PEG Ratio

    1.2

  • Market Cap Cr

    113341.8

  • Price to Book Ratio

    372.9

  • EPS

    73.7

  • Dividend

    1000 ()

  • Relative Strength Index

    50.16

  • Money Flow Index

    53.17

  • MACD Signal

    -34.95

  • Average True Range

    126.34

Investment Ratings

  • Master Rating:

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Divi's Laboratories Synopsis

NSE-Medical-Generic Drugs

Divi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 6798.61 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2021. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
  • Market Cap

    111,998.30

  • Sales

    8,103.18

  • Shares in Float

    12.74

  • No of Funds

    808

  • Yield

    0.46

  • Book Value

    12.5

  • U/D Vol Ratio

    1

  • LTDebt/Equity

  • Alpha

    0.01

  • Beta

    0.83

Divi's Laboratories Ownership
Divi's Laboratories Management

Divi's Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Divi's Laboratories Financials

Divi's Laboratories Technicals

EMA & SMA

CURRENT PRICE

EMA

Divi's Laboratories Resistance and Support

Divi's Laboratories Delivery and Volume

Divi's Laboratories Price Change Analysis

Corporate Action

MF Shareholding

Similar Stocks

Videos

About Company

News

FAQs

Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.

Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.

Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).

Divi's Laboratories share price is

Open Demat Account